Athenex, Inc. (NASDAQ:ATNX) clinical stage biopharmaceutical firm, is reporting third quarter earnings results on Thursday 5th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.43 per share.
For the full year, analysts predict revenues of $ 131.11 million, while looking forward to loss of $ 1.63 per share.
Previous Quarter Performance
Athenex, Inc. outlined loss for the second quarter of $ 0.41 per share, from the revenue of $ 40.17 million. The quarterly revenues extended 80.95 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.36 per share from $ 25.46 million in revenue. The bottom line results missed street analysts by $ 0.05 or 13.89 percent, at the same time, top line results outshined analysts by $ 14.71 million or 57.78 percent.
Stock Performance
Shares of Athenex, Inc. traded up $ 0.20 or 1.67 percent on Wednesday, reaching $ 12.16 with volume of 689.50 thousand shares. Athenex, Inc. has traded high as $ 12.40 and has cracked $ 11.64 on the downward trend
The closing price of $ 12.16, representing a 112.43 % increase from the 52 week low of $ 5.63 and a 34.82 % decrease over the 52 week high of $ 18.35.
The company has a market capital of $ 1.13 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 26th October 2020, initiated by SVB Leerink at Outperform rating, with $ 22.00 target price.
Conference Call
Athenex, Inc. will be hosting a conference call at 8:00 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.athenex.com
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The companys Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.
